UNSPSC 51122400: Combination antianginals

This classification denotes combination drugs that consist of various combined compounds that deal with that cardiovascular disorder characterized by paroxysmal pain consequent to MYOCARDIAL ISCHEMIA usually of distinctive character, location and radiation, a condition commonly called Angina Pectoris, and hence the name (for these preparations) ANTIANGINALS. Typical combination antianginal constituents are mannitol hexanitrate and pentaerythritol tetranitrate.

UNSPSC 51122400 Combination antianginals is a Class code encompassing pharmaceutical medications supplied to state and local emergency response, health agency, and healthcare facility operations. State and local governments procure these medications—typically beta-blockers, calcium-channel blockers, adenosine, and epinephrine formulations—for use by fire rescue departments, public health agencies, and cooperative purchasing consortia serving multiple jurisdictions. Recent solicitations show state and local buyers acquiring these drugs through sealed-bid procurements, cooperative purchasing agreements, and market-intelligence RFIs that precede larger pharmaceutical contracting initiatives. Issuing bodies include city purchasing departments (Tampa), state health and human services commissions (Texas), and multistate cooperative purchasing alliances (Minnesota). The work involves sourcing specific medication line items with strict expiration-date and shelf-life requirements, arranging rapid delivery, warranting product quality, and managing logistics including expired-material pickup and replacement cycles.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) on April 24, 2026, for Advanced Life Support Medications to be used by Tampa Fire Rescue, with a due date of April 8, 2026, and an estimated contract value of $40,000—soliciting Labetalol, Epinephrine, Adenosine, and Diltiazem in specified quantities with nine-month minimum expiration dates and ten-day delivery windows. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling future competitive solicitation for direct pharmacy-to-manufacturer relationships. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered through the Minnesota Department of Administration's Office of State Procurement, issued an RFP due March 26, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products across participating state and local facilities, including Oregon, with awarded vendors taking effect July 1, 2026, and a two-year base term. MMCAP's procurement emphasizes price competitiveness (75 percent weighting), cGMP and DSCSA compliance, and relationships with AmerisourceBergen, Cardinal Health, and Morris & Dickson as authorized wholesalers.